Clinical Trials Logo

Hemophilia B With Inhibitor clinical trials

View clinical trials related to Hemophilia B With Inhibitor.

Filter by:

NCT ID: NCT03619863 Active, not recruiting - Clinical trials for Hemophilia A With Inhibitor

ATHN 7: Hemophilia Natural History Study

ATHN 7
Start date: October 24, 2018
Phase:
Study type: Observational [Patient Registry]

This is a real-world study of the safety of the treatments used for people with hemophilia. The study will follow people with hemophilia A or B from across the country for about 4 years as they receive treatment. The hemophilia treatment center (HTC) physician and participant will decide on the FDA-approved treatment to be used which may include non-factor products, bypassing agents, or clotting factor replacement products. The goal of this research is to study the use of hemophilia treatment products and their outcomes.

NCT ID: NCT03407651 Completed - Clinical trials for Hemophilia A With Inhibitor

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Start date: December 18, 2017
Phase: Phase 2
Study type: Interventional

Phase 2, multi-center, open-label study designed to evaluate the PK, bioavailability, PD, efficacy and safety of a daily subcutaneous [SC] treatment regimen with MarzAA for bleeding prophylaxis in 12 adult subjects with hemophilia A or B with an inhibitor and history of frequent spontaneous bleeding episodes.

NCT ID: NCT03372993 Completed - Clinical trials for Hemophilia A With Inhibitor

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Start date: June 13, 2016
Phase:
Study type: Observational

This study evaluates the immunogenicity of the biosimilar rFVIIa (AryoSeven) in subjects receiving AryoSeven in real-life clinical practice.